#Austria #Avant Technologies #Diabetes Therapy #EPITA Symposium #Igls

Avant Technologies at the 15th EPITA Symposium

Avant Technologies, Inc., recognized for its innovative approaches in biotechnology, is actively participating in the 15th European Pancreas and Islet Transplantation Association (EPITA) Symposium, which is taking place from January 25 to 27, 2026, in Igls, Austria. This event is a landmark gathering of leading scientists, clinicians, and industry experts focused on advancing biological treatments for diabetes. The symposium addresses various topics, including islet transplantation and beta cell replacement therapies, aiming to foster collaboration and innovation in diabetes treatment.

As a company that specializes in developing cell-based therapies for diabetes and age-related disorders, Avant Technologies stands out as a pioneer in immunosuppression-free cell therapy solutions. Dr. Eva Maria Lilli Brandtner is representing Avant at the symposium, where she is evaluating advanced cell types that could potentially revolutionize diabetes therapies using the company's proprietary Cell-in-a-Box® technology. This platform, created in collaboration with SGAustria, offers a revolutionary microencapsulation method that secures transplanted insulin-producing cells against immune rejection without the risks associated with traditional immunosuppression practices, such as tumor formation or infections.

Dr. Brandtner commented on the potential breakthrough encapsulated stem cell-derived beta cells offer. "While these cells can provide a sustainable source of insulin, protecting them from the immune system remains a critical challenge," she stated. Avant's approach with the Cell-in-a-Box® technology effectively solves this issue, enhancing the possibility of providing beta cell replacement therapies for patients with type 1 and insulin-dependent type 2 diabetes globally.

Avant Technologies' participation in EPITA underscores its commitment to enhancing healthcare through innovative methods of cell therapy. By engaging in discussions with global leaders in the field, the company seeks to solidify its role within the diabetes care community and highlight its dedication to making safe, efficient cell therapies available to a broader audience.

About Avant Technologies, Inc.

Avant Technologies is an emerging player in the biotechnology sector, zeroing in on the discovery and development of genetically modified cell lines. The company undertakes joint venture and licensing agreements to advance next-generation cell-based solutions addressing unmet medical needs.

About SGAustria Pte. Ltd.

SGAustria, headquartered in Singapore, is a leading biotechnology firm specializing in GMP-grade cell products, clinically proven cell encapsulation technologies, and the development of cell lines. With over 50 peer-reviewed publications backing their innovations, SGAustria collaborates with various global biotech enterprises to fuel advancements in therapeutic solutions.

For further insights into Avant’s pioneering work in biotechnology and their innovative cell-based therapies, visit their website or follow their social media platforms. Avant Technologies is at the forefront of transforming diabetes treatment, with ongoing initiatives aimed at addressing the critical challenges faced by patients globally.